Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
If approved or authorized, Paxlovid would be the first oral antiviral of its kind, to combat SARS-CoV-2
This test is inexpensive and results are available immediately as compared to the genetic test
The rise in cases amongst the young is a cause for concern. A few specialists gave us a perspective on the issue
Data demonstrates Ronapreve reduced risk of hospitalisation in certain patients and reduced risk of symptomatic Covid-19 infections in people exposed to the virus
The company expects to begin shipping this product before the end of its fiscal first quarter, ending December 31, 2021
Evidence also shows better immune response to virus among users of spray
The submission is based on Phase 2/3 study of mRNA-1273 in children ages 6 to 11
In the overall study population through Day 28, no deaths were reported in patients who received Paxlovid as compared to 10 deaths in patients who received placebo
Trivector Biomed has been promoting its Novaerus air disinfection solution across hospitals and health care facilities across India.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
